Skip to main content
. 2019 Jun 27;105(4):1074–1080. doi: 10.3324/haematol.2019.220657

Figure 2.

Figure 2.

Subgroup analysis of overall survival in the intention-to-treat population for patients treated with VMP or Rd-R. VMP: bortezomib-melphalan-prednisone; Rd-R: lenalidomide-dexamethasone followed by lenalidomide maintenance; HR: hazard ratio; 95% CI: 95% confidence interval; ISS: International Staging System.